MetaCap

Apollomics (APLM) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Apollomics (APLM) has outperformed Xilio Therapeutics (XLO) over the past year, gaining 16.6% versus a loss of 21.7%. Apollomics is the larger company by market cap ($62.7 million vs $58.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APLM+16.64%XLO-21.71%
+106%+30%-45%
Oct 7, 20251 yearOct 7, 2026
APLM-97.83%XLO-96.77%
+157%+22%-112%
Nov 22, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APLM versus XLO key metrics
MetricAPLMXLO
Share price$21.50$8.92
Market cap$62.67M$58.69M
1-day change0.00%-1.00%
YTD return+15.00%+0.56%
1-year return+16.64%-21.71%
EPS (TTM)$-7.57$-0.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$42.12$12.59
52-week low$10.01$6.47
Distance from 52-week high-48.96%-29.13%
Average volume21.61K19.05K
Shares outstanding2.91M6.58M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • APLM has outperformed XLO by 38.3 percentage points over the past year.

APLM vs XLO FAQ

Which is bigger, Apollomics or Xilio Therapeutics?

Apollomics (APLM) is larger, with a market capitalization of $62.67M compared with $58.69M for Xilio Therapeutics (XLO).

Which stock has performed better over the past year, APLM or XLO?

APLM returned +16.64% over the past 12 months, compared with -21.71% for XLO (price return, excluding dividends). Past performance does not predict future results.

Are Apollomics and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons